Kilpatrick Townsend expands patent litigation team
Law firm Kilpatrick Townsend & Stockton has announced the addition of Stuart Pollack to the firm’s New York office as a partner on the patent litigation team.
Pfizer fights approval of generic Ibrance
Pfizer is seeking to block a generic version of its cancer drug Ibrance from entering the market until the patent covering the drug expires in May 2036.
Foley & Lardner opens new Salt Lake litigation office
Foley & Lardner has hired a team of four former Maschoff Brennan attorneys to run a new IP litigation office in Salt Lake City.
Azurity sues Bionpharma over newly issued patent
Azurity Pharmaceuticals has sued Massachusetts drug company Bionpharma, claiming that its generic of Azurity’s Epaned product infringes on a brand new patent.
Big pharma supports Apple health sensor en banc bid
Apple has secured the backing of a major pharmaceutical industry trade association, as it seeks to persuade the US Court of Appeals for the Federal Circuit to revisit a case centring on a pair of health sensor patents.
AstraZeneca wins patent infringement case over Farxiga generic
AstraZeneca has convinced a federal court to uphold challenged claims of a patent related to its diabetes drug Farxiga.
Dems pressure Biden to share Moderna vaccine tech
A group of 12 Democratic Party members, including Senator Elizabeth Warren, have co-signed a letter calling for the Biden administration to share Moderna’s vaccine technology.
Jazz Pharma accused of pay-for-delay deals over Xyrem
Molina Healthcare claims that Jazz Pharmaceuticals delayed generics of its flagship narcolepsy drug Xyrem and hiked the drug prices to increase profits when it was on the verge of bankruptcy.
Globus launches patent suit over spinal implant tech
Medical device company, Globus Medical, has filed a lawsuit against competitor Life Spine, alleging infringement of seven different patents related to spinal tech implant technology.
Bayer, Meda sue Apotex over nasal spray
Bayer Healthcare and drug importer Meda Pharmaceuticals have sued generic manufacturer Apotex, alleging that its planned generic nasal spray infringes on Bayer’s Astepro patents.
